Answers are grounded in this paper and cite their sources.
Background Sepsis is a life-threatening syndrome caused by a dysregulated host response to infection, leading to substantial morbidity and mortality. Reliable biomarkers that support early diagnosis and risk stratification are still in great need. Gelsolin (GSN), an actin-binding protein involved in cytoskeletal remodeling, actin scavenging, and inflammatory regulation, has been proposed as a potential biomarker in sepsis, but the available clinical evidence has not been systematically summarized. Methods PubMed, Scopus, Web of Science, Embase, Cochrane Library and clinical trial registries were searched from database inception to July 26, 2026. Original studies that measured circulating GSN levels in adult patients with sepsis and reported either survival outcomes or comparisons with a control group were eligible. The ratio of means (ROM) was used to compare GSN levels between non-survivors and survivors. For diagnostic analyses, sensitivity, specificity, likelihood ratios, diagnostic odds ratios (ORs), and post-test probabilities were summarized when sufficient data were available. Results Eight studies met the inclusion criteria. In seven studies reporting survival outcomes, GSN levels were significantly lower in non-survivors than in survivors (ROM = 0.62, 95% CI:0.53-0.73, P < 0.00001), with high statistical heterogeneity ( I 2 = 74%). One study reported an admission plasma GSN threshold of 113.6 mg/L that showed prognostic discrimination for 28-day mortality; however, this single study derived threshold should be considered exploratory because it requires external validation and may not be generalizable given variations in assay methods and reported cut-off values across studies. Three studies were included in the exploratory diagnostic analysis. The pooled sensitivity was 0.81 (95% CI:0.71-0.89), whereas specificity was modest at 0.61 (95% CI:0.49-0.72) with substantial heterogeneity across studies ( I 2 = 90.6%), indicating considerable variability in false-positive classification. The positive likelihood ratio was 2.19 and the diagnostic OR was 6.38; however, these estimates should be interpreted cautiously because of the limited number of studies, heterogeneous comparator groups, and variability in diagnostic settings. Conclusions Lower circulating GSN levels are associated with mortality in patients with sepsis and may have value for early prognostic risk stratification. However, because GSN is reduced in several inflammatory and tissue-injury conditions and because diagnostic specificity was modest with substantial heterogeneity, GSN should not be considered a stand-alone diagnostic biomarker for sepsis. Further larger multicenter prospective studies using standardized assays and clinically relevant comparator groups are needed to validate its prognostic and diagnostic utility. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD420261463914.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: